Why the study?
Does sitaxsentan prevent matrix metalloproteinase activation and left ventricular dilation in rats post-myocardial infarction?
Does sitaxsentan prevent matrix metalloproteinase activation and left ventricular dilation in rats post-myocardial infarction?
Inhibition of ETA receptors with sitaxsentan prevents MMP activation and left ventricular dilation in a rat model of post-myocardial infarction remodeling.
Answers are grounded in this paper and cite their sources.
Should not alter post-MI care; hypothesis-generating for ETA blockade limiting experimental remodeling.
Endothelin (ET) A (ET(A)) receptors activate matrix metalloproteinases (MMP). Since endothelin-1 (ET) is increased in myocardium late postmyocardial infarction (MI), we hypothesized that stimulation of ET(A) receptors contributes to activation of myocardial MMPs late post-MI. Three days post-MI, rats were randomized to treatment with the ET(A)-selective receptor antagonist sitaxsentan (n = 12) or a control group (n = 12). Six weeks later, there were rightward shifts of the left ventricular (LV) end-diastolic and end-systolic pressure-volume relationships, as measured ex vivo by the isovolumic Langendorff technique. Both shifts were markedly attenuated by sitaxsentan. In LV myocardium remote from the infarct, the activities of MMP-1, MMP-2, and MMP-9 were increased in the post-MI group, and the increases were prevented by sitaxsentan treatment. Expression of tissue inhibitor of MMP-1 was decreased post-MI, and the decrease was prevented by sitaxsentan treatment. Chronic post-MI remodeling is associated with activation of MMPs in myocardium remote from the infarct. Inhibition of ET(A) receptors prevents MMP activation and LV dilation, suggesting that ET, acting via the ET(A) receptor, contributes to chronic post-MI remodeling by its effects on MMP activity.
No takes yet. Share an insight, caveat, or question.
Podesser et al. (2001) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: